Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleMETABOLISM, TRANSPORT, AND PHARMACOGENOMICS

Pharmacogenetics of Deoxycytidine Kinase: Identification and Characterization of Novel Genetic Variants

Jatinder K. Lamba, Kristine Crews, Stanley Pounds, Erin G. Schuetz, Jessica Gresham, Varsha Gandhi, William Plunkett, Jeffrey Rubnitz and Raul Ribeiro
Journal of Pharmacology and Experimental Therapeutics December 2007, 323 (3) 935-945; DOI: https://doi.org/10.1124/jpet.107.128595
Jatinder K. Lamba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kristine Crews
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stanley Pounds
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Erin G. Schuetz
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jessica Gresham
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Varsha Gandhi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
William Plunkett
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeffrey Rubnitz
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Raul Ribeiro
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Deoxycytidine kinase (DCK) is a rate-limiting enzyme in the activation of nucleoside analogs such as cytarabine (ara-C), gemcitabine, clofarabine, and others. The present study was undertaken to identify and to determine the functional consequences of genetic variants in DCK. We sequenced 1.5 kilobases of the DCK proximal promoter and all seven coding exons in International HapMap Project panels (n = 90 each) with European (Centre d' Etude du Polymorphisme Humain; CEPH) or African (Yoruba people in Ibadan, Nigeria; YRI) ancestry. Sixty-four genetic polymorphisms, including three nonsynonymous coding changes (I24V, A119G, and P122S) were identified. Compared with DCK-wild-type (WT) protein, the activity of the recombinant DCK24Val, DCK119Gly, and DCK122Ser proteins was 85 ± 5, 66 ± 3, and 43 ± 4%, respectively. DCK119Gly and DCK122Ser mutants had lower Km (p < 0.01) and Vmax (p < 0.001) compared with DCK-WT protein. Lymphoblast cell lines from subjects heterozygous for the coding changes had significantly lower DCK activity compared with homozygous WT subjects. Ethnic differences were observed, with African ancestry subjects demonstrating significantly higher DCK mRNA expression compared with subjects with European ancestry. In both CEPH and YRI subjects, the C allele of a 3′-untranslated region single-nucleotide polymorphism (SNP) (35708 C>T) was significantly associated with lower DCK mRNA expression. This SNP was strongly linked with other intronic SNPs, forming a major haplotype block in both ethnic groups. In an exploratory analysis, the 35708C allele was also associated with lower blast ara-C-5′-triphosphate (ara-CTP) levels in acute myeloid leukemia patients receiving ara-C as continuous infusion. These results suggest that genetic variation in DCK influences its activity and expression and may predict the variability observed in intracellular levels of the ara-C active metabolite ara-CTP.

Footnotes

  • This work is supported in part by the National Institutes of Health/National Institute of General Medical Sciences Pharmacogenetics Research Network and Database (U01GM61374; http://www.pharmgkb.org) under Grant U01 GM61393; in part by the Cancer Center Support Grant CA-21765; and by the American Lebanese Syrian Associated Charities. J.G. was supported in part by Grant 5 R25 CA23944 from the National Cancer Institute.

  • Article, publication date, and citation information can be found at http://jpet.aspetjournals.org.

  • doi:10.1124/jpet.107.128595.

  • ABBREVIATIONS: ara-C, 1-β-d-arabinofuranosyl-cytosine (cytarabine); AML, acute myeloid leukemia; ara-CTP, ara-C-5′-triphosphate; DCK, deoxycytidine kinase; hENT1, human equilibrative nucleoside transporter; LD, linage disequilibrium; mt, mutant; SNP, single nucleotide polymorphism; HapMap, Haplotype Map (of human genome); CdA, cladribine; PCR, polymerase chain reaction; CEPH, Centre d' Etude du Polymorphisme Humain; YRI, Yoruba people in Ibadan, Nigeria; UTR, untranslated region; WT, wild-type; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; CT, cycle threshold; ERS, Glu-Arg-Ser; SR, serine/arginine; IVS, intervening sequence (intron).

    • Received July 22, 2007.
    • Accepted September 6, 2007.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 384 (2)
Journal of Pharmacology and Experimental Therapeutics
Vol. 384, Issue 2
1 Feb 2023
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Pharmacogenetics of Deoxycytidine Kinase: Identification and Characterization of Novel Genetic Variants
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleMETABOLISM, TRANSPORT, AND PHARMACOGENOMICS

Pharmacogenetics of Deoxycytidine Kinase: Identification and Characterization of Novel Genetic Variants

Jatinder K. Lamba, Kristine Crews, Stanley Pounds, Erin G. Schuetz, Jessica Gresham, Varsha Gandhi, William Plunkett, Jeffrey Rubnitz and Raul Ribeiro
Journal of Pharmacology and Experimental Therapeutics December 1, 2007, 323 (3) 935-945; DOI: https://doi.org/10.1124/jpet.107.128595

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleMETABOLISM, TRANSPORT, AND PHARMACOGENOMICS

Pharmacogenetics of Deoxycytidine Kinase: Identification and Characterization of Novel Genetic Variants

Jatinder K. Lamba, Kristine Crews, Stanley Pounds, Erin G. Schuetz, Jessica Gresham, Varsha Gandhi, William Plunkett, Jeffrey Rubnitz and Raul Ribeiro
Journal of Pharmacology and Experimental Therapeutics December 1, 2007, 323 (3) 935-945; DOI: https://doi.org/10.1124/jpet.107.128595
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • HDL Mimetic 4F Modulates Aβ Distribution in Brain and Plasma
  • AOX1 Inhibition by Gefitinib, Erlotinib, and Metabolites
  • Catalytic Activity of CYP2C9 Variants
Show more Metabolism, Transport, and Pharmacogenomics

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics